John Overdeck’s Arm ARM Stock Holding History

John Overdeck’s Portfolio ARM Stock Details ARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5M	Sell	14,100 -67,500	-83%	-$17.9M	﹤0.01%	2147
2026 Q1	$12.3M	Buy	81,600 +6,600	+9%	+$801K	0.01%	1266
2025 Q4	$8.2M	Buy	75,000 +73,000	+3,650%	+$10.6M	0.01%	1261
2025 Q3	$283K	Buy	+2,000	New	+$291K	﹤0.01%	3240

Other funds holding ARM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

John Overdeck's ARM Position: Q2 2026 in Review

John Overdeck increased its Arm (ARM) stake by 14% in Q2 2026, buying an estimated $21.3M and bringing the position to 660,156 shares worth $234M. The position accounts for 0.17% of the portfolio, ranked #124.

John Overdeck first reported a position in ARM in Q3 2025 and has held it in 4 quarters since. 955 funds tracked by Wall St. Rank hold ARM as of Q2 2026.

John Overdeck held 660,156 shares of Arm worth $234M as of Q2 2026.
John Overdeck bought 80,118 Arm shares in Q2 2026, an estimated $21.3M.
Arm made up 0.17% of John Overdeck's portfolio in Q2 2026, its #124 holding.
John Overdeck first reported a position in Arm in Q3 2025 and has held it in 4 quarters since.
955 funds tracked by Wall St. Rank held Arm as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.